Ohcanbohtosat - David Back

Aiddostahte ozu
  1. 1
    The challenge of HIV treatment in an era of polypharmacy

    The challenge of HIV treatment in an era of polypharmacy Dahkki David Back, Catia Marzolini

    Almmustuhtton 2020
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Interaction Between Amiodarone and Sofosbuvir-based Treatment for Hepatitis C Virus Infection: Potential Mechanisms and Lessons to be Learned

    Interaction Between Amiodarone and Sofosbuvir-based Treatment for Hepatitis C Virus Infection: Potential Mechanisms and Lessons to be Learned Dahkki David Back, David M. Burger

    Almmustuhtton 2015
    Viečča ollesdeavstta Viečča ollesdeavstta
    Carta
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals

    New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals Dahkki Kay Seden, David Back, Saye Khoo

    Almmustuhtton 2010
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Maraviroc: Pharmacokinetics and drug Interactions

    Maraviroc: Pharmacokinetics and drug Interactions Dahkki Sylvie Abel, David Back, Manoli Vourvahis

    Almmustuhtton 2009
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes

    Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes Dahkki Victoria A. Eagling, John Tjia, David Back

    Almmustuhtton 1998
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors

    Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors Dahkki Louise Profit, Victoria A. Eagling, David Back

    Almmustuhtton 1999
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir

    Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir Dahkki Victoria A. Eagling, David Back, Michael Barry

    Almmustuhtton 1997
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    Darunavir: Pharmacokinetics and Drug Interactions

    Darunavir: Pharmacokinetics and Drug Interactions Dahkki David Back, Vanitha Sekar, Richard M. W. Hoetelmans

    Almmustuhtton 2008
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  9. 9
    Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Fetal Compartment (Placenta and Amniotic Fluid)

    Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Fetal Compartment (Placenta and Amniotic Fluid) Dahkki Laura Else, Stephen Taylor, David Back, Saye Khoo

    Almmustuhtton 2011
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  10. 10
    Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells

    Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells Dahkki Philip Martin, R Riley, David Back, Andrew Owen

    Almmustuhtton 2007
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  11. 11
    Cobicistat versus ritonavir boosting and differences in the drug–drug interaction profiles with co-medications

    Cobicistat versus ritonavir boosting and differences in the drug–drug interaction profiles with co-medications Dahkki Catia Marzolini, Sara Gibbons, Saye Khoo, David Back

    Almmustuhtton 2016
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  12. 12
    Differences in the cytochrome <i>P</i>-450 isoenzymes involved in the 2-hydroxylation of oestradiol and 17 α-ethinyloestradiol. Relative activities of rat and human liver enzymes

    Differences in the cytochrome <i>P</i>-450 isoenzymes involved in the 2-hydroxylation of oestradiol and 17 α-ethinyloestradiol. Relative activities of rat and human liver enzymes Dahkki S. Ball, Lesley M. Forrester, C. Roland Wolf, David Back

    Almmustuhtton 1990
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  13. 13
    Stopping antiretroviral therapy

    Stopping antiretroviral therapy Dahkki Stephen Taylor, Marta Boffito, Saye Khoo, Erasmus Smit, David Back

    Almmustuhtton 2007
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  14. 14
    Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine

    Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine Dahkki Daryl Hodge, David Back, Sara Gibbons, Saye Khoo, Catia Marzolini

    Almmustuhtton 2021
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  15. 15
    Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro

    Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro Dahkki Patrick G. Hoggard, Stephen Kewn, Michael Barry, Saye Khoo, David Back

    Almmustuhtton 1997
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  16. 16
    Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients

    Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients Dahkki Concepta Merry, Michael Barry, Fiona Mulcahy, Kathryn L. Halifax, David Back

    Almmustuhtton 1997
    Viečča ollesdeavstta
    Carta
    Lasit oiddohiidda
    Furkejuvvon:
  17. 17
    Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine

    Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine Dahkki Beth Williamson, Kelly E. Dooley, Yuan Zhang, David Back, Andrew Owen

    Almmustuhtton 2013
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  18. 18
    The pharmacokinetics of methadone in HIV‐positive patients receiving the non‐nucleoside reverse transcriptase inhibitor efavirenz

    The pharmacokinetics of methadone in HIV‐positive patients receiving the non‐nucleoside reverse transcriptase inhibitor efavirenz Dahkki S Clarke, Fiona Mulcahy, John Tjia, Helen Reynolds, Sara E. Gibbons, Michael Barry, David Back

    Almmustuhtton 2001
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  19. 19
    Pharmacokinetic Interactions of Nevirapine and Methadone and Guidelines for Use of Nevirapine to Treat Injection Drug Users

    Pharmacokinetic Interactions of Nevirapine and Methadone and Guidelines for Use of Nevirapine to Treat Injection Drug Users Dahkki S Clarke, Fiona Mulcahy, John Tjia, Helen Reynolds, Sara E. Gibbons, Michael Barry, David Back

    Almmustuhtton 2001
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  20. 20
    Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect

    Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect Dahkki Felix Stader, Saye Khoo, Marcel Stoeckle, David Back, Hans H. Hirsch, Manuel Battegay, Catia Marzolini

    Almmustuhtton 2020
    Viečča ollesdeavstta Viečča ollesdeavstta
    Carta
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: